Efficacy and safety of tirofiban in the prevention of thrombus during stent assisted embolization of intracranial aneurysms

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031383

Enrollment

Unknown

Registered

2020-03-29

Start date

2020-09-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial aneurysms

Interventions

experimental groupA:tirofiban0.15µg/(kg·min)

experimental group B:Intravenously push 10µg/kg for 3-5min, then 0.15µg/(kg·min) intravenously

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with ruptured intracranial aneurysms receiving tent-asisted coil embolization proved by DSA; 2. Patients with onset time less than 72 hours; 3. Aged >= 18 years old and <= 75 years old.

Exclusion criteria

Exclusion criteria: 1. Patients with definite moyamoya disease, cerebral vascular malformations and internal arteriovenous fistula; 2. Patients taking anticoagulant and antiplatelet drugs; 3. Patients with hematological diseases; 4. Patients with previous uremia, hepatic cirrhosis and cancers.

Design outcomes

Primary

Measure	Time frame
incidence of cerebral infarction;	—

Countries

China

Contacts

Public ContactHao Yunfei

Gansu Provincial People's Hospital

52119356@qq.com+86 18893114576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026